Financial analysts and quantitative market forecasting models tracking Lucid Diagnostics (traded under ticker LUCD) project a wide spectrum of potential trading ranges for the micro-cap equity throughout the year. Wall Street consensus twelve-month price targets published by specialized biotech analysts average higher, hovering between $2.00 and $4.19 per share, implying significant percentage upside if commercial test volumes scale rapidly. Conversely, algorithmic models and conservative risk platforms project more modest or defensive trading bands, emphasizing ongoing net operating losses and early-stage commercialization execution timelines.